Not All DOACs Have Same GI-Bleeding Risk
Rivaroxaban is associated with higher rates of gastrointestinal bleeding compared with other direct oral anticoagulants (DOACs), regardless…
Direct Oral Anticoagulants
-
Not All DOACs Have Same GI-Bleeding Risk
Rivaroxaban is associated with higher rates of gastrointestinal bleeding compared with other direct oral anticoagulants (DOACs), regardless... -
DOAC-prompted Bleeding Fatal in Some Patients, Despite Successful Reversal in Many
Despite a high rate of effective hemostasis with reversal agents following major bleeding tied to direct oral... -
Outpatient Management of Pulmonary Embolism
Historically, patients diagnosed with pulmonary embolism (PE) initially have been managed as inpatients. This practice stemmed from...
DOAC-prompted Bleeding Fatal in Some Patients, Despite Successful Reversal in Many
Despite a high rate of effective hemostasis with reversal agents following major bleeding tied to direct oral…
Outpatient Management of Pulmonary Embolism
Historically, patients diagnosed with pulmonary embolism (PE) initially have been managed as inpatients. This practice stemmed from…
A Case Example: Reversing Anticoagulant Dabigatran with Idarucizumab
The Case A 75-year-old man presents to your emergency department via paramedics. His transport time was about…
New-Drug Details: Reversing Anticoagulant Dabigatran with Idarucizumab
Idarucizumab (Praxbind) is the first and only specific reversal agent for a novel oral anticoagulant (NOAC) approved…
Should You Use Direct Oral Anticoagulants for Cancer-Associated VTE?
The Case A 73-year-old man currently undergoing chemotherapy for colon cancer presents to the emergency department with…
New Developments in Direct Oral Anticoagulant Safety and Indications
Much has changed in the realm of oral anticoagulation over the past few years. Beginning with the…